# Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

> **NCT06085638** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Tamibarotene
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06085638
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09-14
- **Primary completion:** 2023-10-20
- **Final completion:** 2023-10-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Zero participants accrued
- **Last updated:** 2024-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06085638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06085638, "Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06085638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*